News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
By Nancy Lapid (Reuters) -GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Daniel Drucker, Ozempic’s father: ‘I’m very conservative. I don’t sell the drugs. I study the drugs’
The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...
Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...
India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...
Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...
Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results